Roche Adds To Oncology Lexicon With BRAF Kinase Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Plexxikon’s PLX-4032 could eventually compete against biologics in the colorectal cancer market.
You may also be interested in...
Plexxikon Deals Kidney Disease Drug To Roche (Updated)
With a three-year financial runway, biotech contends the deal validates its discovery-only business model.
Plexxikon Deals Kidney Disease Drug To Roche (Updated)
With a three-year financial runway, biotech contends the deal validates its discovery-only business model.
Plexxikon Deals Kidney Disease Drug To Roche
With a three-year financial runway, biotech contends the deal validates its discovery-only business model.